Neurocrine Biosciences said Monday that it would buy Soleno Therapeutics and its treatment for Prader-Willi syndrome for $2.9 billion.  Neurocrine is paying $53 a share for Soleno, a 34% premium to its closing price on Thursday.  Soleno’s drug, Vykat, was approved in March 2025 to treat hyperphagia in patients with the rare genetic disease . Hyperphagia is one of the defining features of Prader-Willi syndrome, causing relentless hunger and leading patients to overeat. Vykat is the only approved treatment for hyperphagia in Prader-Willi patients.  Continue to STAT+ to read the full story...
STAT News published a clinical update in Research Highlights on 06 Apr 2026.
The item focuses on STAT+: Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal.
Review the original article for the full source wording and details.